LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.

Voskuilen, Charlotte S / van der Heijden, Michiel S / van Rhijn, Bas W G

2019 Volume 76, Issue 6, Page(s) 870–871

MeSH term(s)	Cisplatin ; Deoxycytidine/analogs & derivatives ; Humans ; Neoadjuvant Therapy ; Prospective Studies ; Urinary Bladder Neoplasms
Chemical Substances	Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2019-07-25
Publishing country	Switzerland
Document type	Journal Article ; Comment
ZDB-ID	193790-x
ISSN	1873-7560 ; 1421-993X ; 0302-2838
ISSN (online)	1873-7560 ; 1421-993X
ISSN	0302-2838
DOI	10.1016/j.eururo.2019.07.019
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1247: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 294: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Reference curves for the normal fetal small bowel and colon diameters; their usefulness in fetuses with suspected dilated bowel.

Lap, Chiara C / Voskuilen, Charlotte S / Pistorius, Lourens R / Mulder, Eduard J H / Visser, Gerard H A / Manten, Gwendolyn T R

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

2019 Volume 33, Issue 4, Page(s) 633–638

Abstract: Objectives: ...

Abstract	Objectives:
MeSH term(s)	Colon/diagnostic imaging ; Female ; Humans ; Intestine, Small/diagnostic imaging ; Longitudinal Studies ; Pregnancy ; Prospective Studies ; Reference Values ; Ultrasonography, Prenatal
Language	English
Publishing date	2019-01-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2077261-0
ISSN	1476-4954 ; 1057-0802 ; 1476-7058
ISSN (online)	1476-4954
ISSN	1057-0802 ; 1476-7058
DOI	10.1080/14767058.2018.1498837
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3510: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Staging

Voskuilen, Charlotte S / van Gennep, Erik J / Einerhand, Sarah M H / Vegt, Erik / Donswijk, Maarten L / Bruining, Annemarie / van der Poel, Henk G / Horenblas, Simon / Hendricksen, Kees / van Rhijn, Bas W G / Mertens, Laura S

European urology oncology

2021 Volume 5, Issue 3, Page(s) 366–369

Abstract: Given the high risk of systemic relapse following initial therapy for muscle-invasive bladder cancer (MIBC), improved pretreatment staging is needed. We evaluated the incremental value ... ...

Abstract	Given the high risk of systemic relapse following initial therapy for muscle-invasive bladder cancer (MIBC), improved pretreatment staging is needed. We evaluated the incremental value of
MeSH term(s)	Fluorodeoxyglucose F18 ; Humans ; Lymphatic Metastasis ; Neoplasm Recurrence, Local ; Positron Emission Tomography Computed Tomography/methods ; Retrospective Studies ; Urinary Bladder Neoplasms/diagnostic imaging ; Urinary Bladder Neoplasms/therapy
Chemical Substances	Fluorodeoxyglucose F18 (0Z5B2CJX4D)
Language	English
Publishing date	2021-02-11
Publishing country	Netherlands
Document type	Journal Article
ISSN	2588-9311
ISSN (online)	2588-9311
DOI	10.1016/j.euo.2021.01.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.

Voskuilen, Charlotte S / van de Kamp, Maaike W / Schuring, Nannet / Mertens, Laura S / Noordzij, Arjen / Pos, Floris / van Rhijn, Bas W G / van der Heijden, Michiel S / Schaake, Eva E

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

2020 Volume 150, Page(s) 275–280

Abstract: Background and purpose: Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC). MMC/capecitabine is an effective replacement for 5FU ... ...

Abstract	Background and purpose: Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC). MMC/capecitabine is an effective replacement for 5FU as a radiosensitizer in other malignancies but has not been studied in bladder cancer. We evaluated the outcomes of MIBC patients treated with concurrent radiation and MMC/capecitabine. Materials and methods: MIBC patients treated with CRT (60 Gy in 5 weeks with single-dose MMC and capecitabine orally twice daily) between 2014 and 2019 were identified. Acute (<90 days) and late toxicity were registered. Endpoints were clinical complete response (cCR) in the bladder assessed by cystoscopy 3 months after CRT, locoregional disease-free survival (LDFS) and the number of salvage cystectomies. Results: We analysed 71 cT2-4aN0-2 M0 MIBC patients (median age 70 years). Twenty-one (30%) patients received neoadjuvant or induction chemotherapy and 14 (20%) patients underwent a pelvic lymph node dissection prior to CRT. All patients received the full dose of planned radiation. Seven (10%) patients experienced acute grade 3-4 toxicities and 2 (3%) patients experienced late grade 3-4 toxicities. Sixty-eight (96%) patients achieved cCR. Eight (11%) patients had a bladder recurrence, of whom 3 (4%) required salvage cystectomy. Two-year LDFS was 79% (95% CI: 68-88) at a median follow-up of 23 (95% CI: 17-28) months. Conclusion: Radiation with concurrent MMC/capecitabine is a well-tolerated bladder-sparing treatment. Severe toxicity is infrequent and locoregional tumor control and short-term disease free survival appear similar to previous studies with MMC/5FU.
MeSH term(s)	Aged ; Antineoplastic Combined Chemotherapy Protocols ; Capecitabine ; Fluorouracil ; Humans ; Mitomycin ; Muscles ; Neoplasm Recurrence, Local ; Tablets ; Urinary Bladder Neoplasms/therapy
Chemical Substances	Tablets ; Mitomycin (50SG953SK6) ; Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2020-08-06
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	605646-5
ISSN	1879-0887 ; 0167-8140
ISSN (online)	1879-0887
ISSN	0167-8140
DOI	10.1016/j.radonc.2020.07.057
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Oncological Outcomes for Patients Harboring Positive Surgical Margins Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Multicentric Study on Behalf of the YAU Urothelial Group.

Cancers

2022 Volume 14, Issue 23

Abstract: Introduction: Adjuvant therapy has no defined role for patients with positive surgical margins (PSMs) following radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). The aim of our study was to describe loco-regional recurrence-free survival ...

Abstract	Introduction: Adjuvant therapy has no defined role for patients with positive surgical margins (PSMs) following radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). The aim of our study was to describe loco-regional recurrence-free survival (LRFS), metastatic-free survival (MFS), recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS) and identify predictors of each endpoint in patients with PSMs following RC for MIBC. Methods: A collaborative retrospective cohort study was conducted on 394 patients with PSMs who underwent RC for MIBC between January 2000 and December 2018 at 10 tertiary referral centers. Patients receiving perioperative radiotherapy were excluded from the study. Kaplan−Meier curves were used to estimate patient survival. Cox regression analysis was used to identify predictors of survival. Results: Median age at surgery was 70 years (IQR 62−76) with 129 (33%) and 204 (52%) patients had pT3 and pT4 tumors, respectively. Nodal metastasis (pN+) was identified in 148 (38%). Soft tissue PSMs were found in 283 (72%) patients, urethral PSMs in 65 (16.5%), and ureteral PSMs were found in 73 (18.5%). The median follow-up time was 44 months (95% CI 32−60). Median LRFS, MRFS, RFS, CSS, and OS were 14 (95% CI 11−17), 12 (95% CI 10−16), 10 (95% CI 8−12), 23 (95% CI 18−33), and 16 months (95% CI 12−19), respectively. On multivariable Cox regression analysis, the pT3−4 stage, pN+ stage, and multifocal PSMs were independent predictors of LRFS, MRFS, RFS, and OS. Adjuvant chemotherapy improved all oncological outcomes studied (p < 0.05). The number of lymph nodes removed was independently associated with better LRFS, MRFS, and RFS. Advanced age at diagnosis was independently associated with worse OS. Conclusion: Patients with PSMs following RC have poor outcomes since half of them will recur within a year and will die of their disease. Among all PSMs types, patients with multifocal PSMs harbor the worst prognosis. We observed a benefit of adjuvant chemotherapy, but clinical trials evaluating innovative adjuvant strategies for these patients remain an unmet need.
Language	English
Publishing date	2022-11-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14235740
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.

van Dijk, Nick / Gil-Jimenez, Alberto / Silina, Karina / van Montfoort, Maurits L / Einerhand, Sarah / Jonkman, Lars / Voskuilen, Charlotte S / Peters, Dennis / Sanders, Joyce / Lubeck, Yoni / Broeks, Annegien / Hooijberg, Erik / Vis, Daniel J / van den Broek, Maries / Wessels, Lodewyk F A / van Rhijn, Bas W G / van der Heijden, Michiel S

Frontiers in immunology

2021 Volume 12, Page(s) 793964

Abstract: Candidate immune biomarkers have been proposed for predicting response to immunotherapy in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. A comprehensive overview of the tumor immune contexture, including Tertiary ... ...

Abstract	Candidate immune biomarkers have been proposed for predicting response to immunotherapy in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. A comprehensive overview of the tumor immune contexture, including Tertiary Lymphoid structures (TLS), is needed to better understand the immunotherapy response in UC. We analyzed tumor sections by quantitative multiplex immunofluorescence to characterize immune cell subsets in various tumor compartments in tumors without pretreatment and tumors exposed to preoperative anti-PD1/CTLA-4 checkpoint inhibitors (NABUCCO trial). Pronounced immune cell presence was found in UC invasive margins compared to tumor and stroma regions. CD8
MeSH term(s)	Aged ; CD8-Positive T-Lymphocytes/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; Cell Differentiation ; Cells, Cultured ; Female ; Fluorescent Antibody Technique ; Forkhead Transcription Factors/metabolism ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Ipilimumab/therapeutic use ; Lymphocyte Activation ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Helper-Inducer/immunology ; Tertiary Lymphoid Structures ; Treatment Outcome ; Tumor Microenvironment ; Urologic Neoplasms ; Urothelium/metabolism ; Urothelium/pathology
Chemical Substances	CTLA-4 Antigen ; FOXP3 protein, human ; Forkhead Transcription Factors ; Immune Checkpoint Inhibitors ; Ipilimumab ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; Nivolumab (31YO63LBSN)
Language	English
Publishing date	2021-12-20
Publishing country	Switzerland
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2021.793964
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer.

Voskuilen, Charlotte S / Bosschieter, Judith / van Werkhoven, Erik / Hendricksen, Kees / Vis, André N / Witteveen, Thelma / Pieters, Bradley R / Burger, Max / Bex, Axel / van der Poel, Henk G / Moonen, Luc M / Horenblas, Simon / Nieuwenhuijzen, Jakko A / van Rhijn, Bas W G

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

2019 Volume 141, Page(s) 130–136

Abstract: Background and purpose: Radical cystectomy (RC) is considered standard treatment for muscle-invasive bladder cancer (BC) and high-risk non-muscle invasive BC. In selected cases, bladder-sparing treatment using brachytherapy can be offered. We examined ... ...

Abstract	Background and purpose: Radical cystectomy (RC) is considered standard treatment for muscle-invasive bladder cancer (BC) and high-risk non-muscle invasive BC. In selected cases, bladder-sparing treatment using brachytherapy can be offered. We examined the outcome after brachytherapy in comparison to RC in terms of survival, complications and bladder preservation in patients with cT1G3-T2N0M0 BC. Materials and methods: Between 1988 and 2016, 301 patients underwent brachytherapy in two centres. Overall survival (OS) and disease specific survival (DSS) after brachytherapy and RC were assessed using Kaplan-Meier curves. Cox proportional hazards modelling was used to determine variables associated with OS and DSS. Local recurrences, bladder preservation and salvage cystectomy (SC) after brachytherapy were reported. Complications after brachytherapy, RC and SC were compared using CTCAE criteria. Results: Median follow-up was 9.6 years (95% confidence interval (CI): 8.8-10.4) after brachytherapy and 10.6 years (95% CI: 10.0-11.2) after RC. Five/10-year OS was 66%/49% after brachytherapy and 68%/53% after RC (p = 0.4). Five/10-year DSS was 73%/67% after brachytherapy and 75%/65% after RC (p = 0.8). Intravesical recurrence occurred in 58/259 brachytherapy patients after which salvage cystectomy was performed in 32 patients. In total, 84% of brachytherapy-treated patients preserved their bladder. The brachytherapy cohort experienced less high grade complications than the RC cohort (p = 0.02). Conclusion: In selected patients with solitary, ≤5 cm cT1G3-T2N0M0 bladder tumours brachytherapy is a bladder-sparing therapy with good survival outcome and with a favourable complication rate compared to RC.
MeSH term(s)	Aged ; Brachytherapy/methods ; Female ; Humans ; Male ; Middle Aged ; Organ Sparing Treatments/methods ; Retrospective Studies ; Survival Analysis ; Treatment Outcome ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/radiotherapy
Language	English
Publishing date	2019-10-17
Publishing country	Ireland
Document type	Journal Article ; Multicenter Study
ZDB-ID	605646-5
ISSN	1879-0887 ; 0167-8140
ISSN (online)	1879-0887
ISSN	0167-8140
DOI	10.1016/j.radonc.2019.09.026
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Hermans, Tom J N / Voskuilen, Charlotte S / van der Heijden, Michiel S / Schmitz-Dräger, Bernd J / Kassouf, Wassim / Seiler, Roland / Kamat, Ashish M / Grivas, Petros / Kiltie, Anne E / Black, Peter C / van Rhijn, Bas W G

Urologic oncology

2017 Volume 36, Issue 9, Page(s) 413–422

Abstract: Background: Approximately half of patients who undergo radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) will succumb to metastatic disease. We summarize the evidence for neoadjuvant radiation (NAR), chemo (NAC), and immunotherapy ( ... ...

Abstract	Background: Approximately half of patients who undergo radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) will succumb to metastatic disease. We summarize the evidence for neoadjuvant radiation (NAR), chemo (NAC), and immunotherapy (checkpoint inhibition) prior to RC for MIBC. Materials and methods: Data were obtained by a search of PubMed, ClinicalTrials.gov, and Cochrane databases for English language articles published from 1925 up to 2017. Results: NAC usage has increased over the last decade, while NAR is rarely administered. Although NAR results in downstaging, its impact on survival is inconclusive. Based on level I evidence, cisplatin-based NAC (CB-NAC) is considered standard of care in cT2-4aN0M0 MIBC. NAC results in a 6% absolute 10-year overall survival (OS) benefit. In-depth analyses of key randomized controlled trials showed that failure to correct for uniform staging, surgical variation, and patient selection compromises the ability to identify factors predictive of response to NAC. The benefit appears to be restricted to patients downstaged to ypT1N0 or less. In these patients, 5-year OS is 80% to 90%. Regarding a number needed to treat of 17, most patients with cT2-4aN0M0 MIBC will be exposed to toxicity without benefit. Possible approaches to reduce overtreatment are suggested in this article and include patient selection, the chosen NAC regimen, and emerging molecular data to predict responsiveness to NAC. Neoadjuvant immunotherapy with checkpoint inhibitors is a promising future perspective currently under investigation. Conclusions: Past studies on NAR show inconclusive results and NAR is rarely administered. Instead, CB-NAC is advised in eligible patients with cT2-4aN0M0 MIBC prior to RC. In the near future, predictive biomarkers will be the key to tailor the use of CB-NAC and reduce harm to nonresponders.
MeSH term(s)	Female ; Humans ; Immunotherapy/methods ; Male ; Neoadjuvant Therapy/methods ; Survival Rate ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/mortality ; Urinary Bladder Neoplasms/pathology
Language	English
Publishing date	2017-11-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2017.10.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4817: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder.

van Doeveren, Thomas / Nakauma-Gonzalez, Jose A / Mason, Andrew S / van Leenders, Geert J L H / Zuiverloon, Tahlita C M / Zwarthoff, Ellen C / Meijssen, Isabelle C / van der Made, Angelique C / van der Heijden, Antoine G / Hendricksen, Kees / van Rhijn, Bas W G / Voskuilen, Charlotte S / van Riet, Job / Dinjens, Winand N M / Dubbink, Hendrikus J / van de Werken, Harmen J G / Boormans, Joost L

International journal of cancer

2020 Volume 148, Issue 4, Page(s) 981–987

Abstract: The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether ... ...

Abstract	The risk of developing urothelial carcinoma of the bladder (UCB) in patients treated by radical nephroureterectomy (RNU) for an upper urinary tract urothelial carcinoma (UTUC) is 22% to 47% in the 2 years after surgery. Subject of debate remains whether UTUC and the subsequent UCB are clonally related or represent separate origins. To investigate the clonal relationship between both entities, we performed targeted DNA sequencing of a panel of 41 genes on matched normal and tumor tissue of 15 primary UTUC patients treated by RNU who later developed 19 UCBs. Based on the detected tumor-specific DNA aberrations, the paired UTUC and UCB(s) of 11 patients (73.3%) showed a clonal relation, whereas in four patients the molecular results did not indicate a clear clonal relationship. Our results support the hypothesis that UCBs following a primary surgically resected UTUC are predominantly clonally derived recurrences and not separate entities.
Language	English
Publishing date	2020-10-13
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	218257-9
ISSN	1097-0215 ; 0020-7136
ISSN (online)	1097-0215
ISSN	0020-7136
DOI	10.1002/ijc.33327
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 478: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 576: Show issues

Order via subito

Details ▾

Article ; Online: Prostate sparing cystectomy for bladder cancer: A two-center study.

Voskuilen, Charlotte S / Fransen van de Putte, Elisabeth E / Pérez-Reggeti, Jose I / van Werkhoven, Erik / Mertens, Laura S / van Rhijn, Bas W G / Saad, Mohamed / Bex, Axel / Cathelineau, Xavier / van der Poel, Henk G / Horenblas, Simon / Sanchez-Salas, Rafael / Meijer, Richard P

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

2018 Volume 44, Issue 9, Page(s) 1446–1452

Abstract: Purpose: To assess long-term functional and oncologic outcomes of prostate sparing cystectomy (PSC) as a sexuality-preserving alternative to radical cystectomy in a selected group of bladder cancer (BC) patients.: Materials and methods: Between 1995 ... ...

Abstract	Purpose: To assess long-term functional and oncologic outcomes of prostate sparing cystectomy (PSC) as a sexuality-preserving alternative to radical cystectomy in a selected group of bladder cancer (BC) patients. Materials and methods: Between 1995 and 2014, 185 BC patients underwent PSC according to one of two standardized procedures at two centers. All patients had received extensive evaluation to rule out prostate cancer and BC at the bladder neck and prostatic urethra (PU), including prostate specific antigen blood analysis, transrectal ultrasound and/or prostate biopsies, PU biopsies and/or PU frozen section analysis. All patients received an orthotopic ileal neobladder. Overall survival (OS) was assessed by Kaplan-Meier estimates. Cumulative incidence of cancer specific mortality, any recurrence and loco-regional recurrence were calculated using competing-risk methods. Finally, functional outcomes (voiding, continence and erectile function) were evaluated. Results: 185 patients (cTa-3N0M0) with a mean age of 57 years (SD: 9) were included. Median follow-up was 7.5 years (IQR: 5.6-10.8). Five-year OS was 71% and 5-year cumulative incidence of recurrence was 31%. Twenty patients (10.8%) had a loco-regional recurrence, two recurrences were in the PU. During follow-up, prostate cancer was detected in six patients (3.2%). Erectile function was preserved in 86.1% of patients, complete daytime and nighttime continence in 95.6% and 70.2%, respectively. Conclusion: This two-center study shows that in men with BC in whom the prostate and PU were proven free of malignancy, PSC would represent a valid treatment option with excellent functional outcome. Oncologic outcomes were comparable to what is known from radical cystoprostatectomy series.
MeSH term(s)	Cystectomy/methods ; Follow-Up Studies ; Forecasting ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Organ Sparing Treatments/methods ; Penile Erection/physiology ; Prospective Studies ; Prostate/surgery ; Treatment Outcome ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/physiopathology ; Urinary Bladder Neoplasms/surgery ; Urination/physiology
Language	English
Publishing date	2018-06-08
Publishing country	England
Document type	Journal Article ; Multicenter Study
ZDB-ID	632519-1
ISSN	1532-2157 ; 0748-7983
ISSN (online)	1532-2157
ISSN	0748-7983
DOI	10.1016/j.ejso.2018.05.032
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1149: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 549: Show issues

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito